Viewing StudyNCT00000958



Ignite Creation Date: 2024-05-05 @ 10:00 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00000958
Status: COMPLETED
Last Update Posted: 2021-11-04
First Post: 1999-11-02

Brief Title: A Placebo-Controlled Phase I Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3 a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1 in Combination With MTP-PEMF59 in Individuals With HIV Infection Placebo Patients Receive MF59 Emulsion Only
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Organization: National Institute of Allergy and Infectious Diseases NIAID

Organization Data

Organization: National Institute of Allergy and Infectious Diseases NIAID
Class: NIH
Study ID: AVEG 103
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Lead Sponsor Class: NIH
Responsible Party: None
Responsible Party Title: None
Responsible Party Type: SPONSOR
Responsible Party Affiliation: None
Old Name: None
Old Organization: None

Collaborators

Name Class
Biocine INDUSTRY